Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the only trans-disciplinary optical biopsy platform, today announced that Cellvizio's clinical value for the management of patients with pancreatic cysts was widely disseminated to the international medical community during the EUS 2014 conference that took place in Chennai, India, from September 18 to 20th.
Help employers find you! Check out all the jobs and post your resume.
